CUL Stock Overview
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Aspira Women's Health Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.81 |
| 52 Week High | US$4.80 |
| 52 Week Low | US$0.81 |
| Beta | 1.5 |
| 11 Month Change | -59.25% |
| 3 Month Change | -66.32% |
| 1 Year Change | n/a |
| 33 Year Change | -98.66% |
| 5 Year Change | -93.17% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| CUL | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -30.3% | -2.4% | 0.6% |
| 1Y | n/a | 0.01% | 3.3% |
Return vs Industry: Insufficient data to determine how CUL performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how CUL performed against the German Market.
Price Volatility
| CUL volatility | |
|---|---|
| CUL Average Weekly Movement | 14.1% |
| Medical Equipment Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: CUL's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CUL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 64 | Nicole Sandford | aspirawh.com |
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company’s products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1’s high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OvaMDx, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass; EndoCheck, a protein biomarker designed to identify ovarian endometriomas; and EndoMDx for the identification of endometriosis.
Aspira Women's Health Inc. Fundamentals Summary
| CUL fundamental statistics | |
|---|---|
| Market cap | €10.84m |
| Earnings (TTM) | -€13.65m |
| Revenue (TTM) | €8.32m |
1.3x
P/S Ratio-0.8x
P/E RatioIs CUL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CUL income statement (TTM) | |
|---|---|
| Revenue | US$8.99m |
| Cost of Revenue | US$3.70m |
| Gross Profit | US$5.29m |
| Other Expenses | US$20.03m |
| Earnings | -US$14.74m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.18 |
| Gross Margin | 58.84% |
| Net Profit Margin | -163.95% |
| Debt/Equity Ratio | -147.6% |
How did CUL perform over the long term?
See historical performance and comparison